Junshi Biosciences Co., Ltd and Rxilient Biotech entered into a collaboration for the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab, through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.

“This extensive collaboration with Rxilient Biotech in Southeast Asia is a vital step for Junshi Biosciences as we strive to expand our global commercialization network,” said Ning LI, CEO of Junshi Biosciences. “Southeast Asia boasts a thriving pharmaceutical innovation environment, flexible drug regulatory policies, and diversified medical security systems, so it has great potential as an emerging market for innovative drugs.”

“The establishment of Rxilient is an important step in its expansion plan to Southeast Asian market and its globalization for CMS,” said Lee Ker Yin, CEO of Rxilient. “Rxilient has formed a team of talented with rich experiences in medical and pharmaceutical industries in Southeast Asia and has engaged gradually in building product lines covering a wide range of therapeutic fields. Based in Singapore, it will radiate to Southeast Asia and thereafter the other global market and strive to build a bridgehead for global Biotech and pharmaceutical companies in Southeast Asia.”